MANKIND PHARMABullish Wedge Pattern is forming.
Wait for Retest.
Than Make Your Position.
Idea shared Only for Educational Purpose.
Next report date
Report period
Q4 2023
EPS estimate
9.62INR
Revenue estimate
24.03 BINR
43.10INR
12.82 BINR
87.43 BINR
64.42 M
About MANKIND PHARMA LTD
Sector
CEO
Sheetal Arora
Headquarters
New Delhi
Website
Employees (FY)
18.47 K
Founded
1986
ISIN
INE634S01028
FIGI
BBG01G9WXG92
Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. It offers products under the brands of Nurokind, Telmikind, Manforce, Unwanted, Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Prega News, Dydroboon, Cefakind, Monticope, and Caldikind. The company was founded by Ramesh Chand Juneja in 1986 and is headquartered in New Delhi, India.
W PATTERN HAS FORMED1 DAY Time Frame- W PATTERN HAS FORMED.
Just keep patience to get supported on 61.80%.
3 times rejection from fib based extention 78.60% and got supported from 50.00% it's time to make new entries.
IDEA SHARED ONLY FOR EDUCATIONAL PURPOSE.
MANKIND PHARMA making breakout from 3-month consolidation rangeMANKIND PAHRMA is making breakout from a 3-month consolidation range. Its relative performance to CNX 500 turned positive, & the momentum indicator, RSI has not gone below its bull support zone of 60 during the entire consolidation period & that indicats strength in its bullish momentum. The structu
3rd of the 3rd is coming in MANKINDIn the weekly timeframe, it is evident that mankind has successfully navigated through its first and second wave, and is now poised for the commencement of its third wave. Transitioning to the daily chart, we observe the initiation of this anticipated third wave, with the completion of its first sub
mankind pharma 4hr time frame buy@ 1819 target @ 1873, 1893, mankind pharma 4hr time frame
buy@ 1819 target @ 1873, 1893, 1899, 1929.70
channel breakout
risk reward 1:2
its just a view trade @ your own risk
sl@ 1766
Mankind Pharma - Daily Bullish MomentumNSE:MANKIND daily chart triangle breakout with price momentum and volume. Macd showing speedy price reaction.
Wait and then make Position.
In the last 6 months, it has given a 50% return.
And now it is consolidating from last 3 months.
This is new IPO, and we can not give so much early commentary on this, I want to build position but I am waiting for the breakout.
If it gives upside breakout, then fresh mid-term pos
MANKIND PHARMA: Triangle breakoutMANKIND PHARMA: Triangle breakout
expect bullish move with proper SL
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MANKIND is 2366.00 INR — it has decreased by 0.75% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange MANKIND PHARMA LIMITED stocks are traded under the ticker MANKIND.
MANKIND PHARMA LIMITED is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
MANKIND stock is 2.68% volatile and has beta coefficient of 0.44. Check out the list of the most volatile stocks — is MANKIND PHARMA LIMITED there?
MANKIND earnings for the last quarter are 12.50 INR per share, whereas the estimation was 12.75 INR resulting in a −1.96% surprise. The estimated earnings for the next quarter are 9.87 INR per share. See more details about MANKIND PHARMA LIMITED earnings.
MANKIND PHARMA LIMITED revenue for the last quarter amounts to 27.08 B INR despite the estimated figure of 27.08 B INR. In the next quarter revenue is expected to reach 23.58 B INR.
Yes, you can track MANKIND PHARMA LIMITED financials in yearly and quarterly reports right on TradingView.
MANKIND stock has risen by 0.81% compared to the previous week, the month change is a 0.37% fall, over the last year MANKIND PHARMA LIMITED has showed a 82.00% increase.
MANKIND net income for the last quarter is 4.54 B INR, while the quarter before that showed 5.01 B INR of net income which accounts for −9.43% change. Track more MANKIND PHARMA LIMITED financial stats to get the full picture.
Today MANKIND PHARMA LIMITED has the market capitalization of 947.79 B, it has increased by 2.44% over the last week.
No, MANKIND doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MANKIND shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MANKIND PHARMA LIMITED stock right from TradingView charts — choose your broker and connect to your account.
As of May 2, 2024, the company has 18.47 K employees. See our rating of the largest employees — is MANKIND PHARMA LIMITED on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MANKIND PHARMA LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MANKIND PHARMA LIMITED stock shows the neutral signal. See more of MANKIND PHARMA LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MANKIND PHARMA LIMITED future price: according to them, MANKIND price has a max estimate of 2520.00 INR and a min estimate of 1750.00 INR. Read a more detailed MANKIND PHARMA LIMITED forecast: see what analysts think of MANKIND PHARMA LIMITED and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MANKIND PHARMA LIMITED EBITDA is 23.61 B INR, and current EBITDA margin is 22.23%. See more stats in MANKIND PHARMA LIMITED financial statements.